keyword
https://read.qxmd.com/read/38528743/c-reactive-protein-as-a-novel-biomarker-for-vitamin-d-deficiency-in-alopecia-areata
#1
JOURNAL ARTICLE
Ahmed Ibrahim AbdElneam, Mohammed Saleh Al-Dhubaibi, Saleh Salem Bahaj, Ghada Farouk Mohammed, Ahmed Kaid Alantry, Lina Mohamed Atef
BACKGROUND: Alopecia areata (AA) is an autoimmune condition characterized by sudden and unpredictable hair loss, with a lifetime incidence of 2%. AA can be divided into three categories: patchy alopecia, alopecia totalis, and alopecia universalis. It can affect a person's psychological health and overall quality of life. Elevated C-reactive protein (CRP) levels in the liver may indicate an inflammatory response in autoimmune diseases. Vitamin D, essential for immune system control and skin health, may be related to AA...
March 2024: Skin Research and Technology
https://read.qxmd.com/read/38523953/ophiasis-alopecia-areata-in-a-patient-with-spondyloarthritis-on-secukinumab-a-case-report-and-review-of-the-literature
#2
Christeebella Akpala, Yue-Ping Zhang, Giang Huong Nguyen
Secukinumab (Cosentyx), an interleukin-17A-targeting biological agent, is commonly prescribed for psoriasis, psoriatic arthritis, and spondyloarthritis (SpA). Alopecia areata (AA), an IL-17-mediated autoimmune disorder characterized by nonscarring hair loss, particularly in an ophiasis pattern, represents a rare adverse effect associated with secukinumab therapy. We present a case of a 46-year-old female with SpA undergoing secukinumab treatment, who developed an ophiasis pattern of AA, subsequently experiencing regrowth upon medication discontinuation...
February 2024: Curēus
https://read.qxmd.com/read/37814732/ophiasis-pattern-alopecia-areata-in-an-infant
#3
Muna Shakhashiro, Sandro Pasagic, Chase L Wilson
Alopecia areata (AA), an autoimmune inflammatory disorder causing non-scarring hair loss, predominantly affects the adult population and is rarely encountered in young infants and neonates. The etiology of this condition remains multifactorial, involving complex interactions between genetic, autoimmune, and environmental factors. In this report, we present a notable case of a four-month-old infant who presented with distinct band-like hair loss on the right inferior lateral forehead, left inferior lateral forehead, and superior middle forehead following a culturally significant head-shaving ritual known as Chudakarana...
September 2023: Curēus
https://read.qxmd.com/read/37559401/a-retrospective-review-of-anthralin-in-petrolatum-in-the-treatment-of-alopecia-areata-in-the-pediatric-population
#4
JOURNAL ARTICLE
Yaron Zafrir, Kimberly Tantuco, Ang J A Tangtatco, Nhung Ho
BACKGROUND/OBJECTIVES: Alopecia areata (AA) is a T-cell driven autoimmune disease, which results in hair loss. This study aims to determine the efficacy, tolerability and safety of different concentrations of anthralin in the treatment of pediatric AA. METHODS: A retrospective cohort study of patients < 18 yo diagnosed with AA treated with anthralin at SickKids Hospital, Toronto dermatology outpatient clinic in 2016 - 2018. Anthralin used at 0.1%, 0.2%, 0.5% and 1% in petrolatum at short contact, at increments of 15 minutes every week until a 1 hr maximum contact achieved...
August 9, 2023: Journal of Cutaneous Medicine and Surgery
https://read.qxmd.com/read/36386728/a-practical-approach-to-the-treatment-of-alopecia-areata
#5
REVIEW
Rachita Dhurat, Richa Sharma
Alopecia areata is an autoimmune condition which usually presents as non-scarring patchy alopecia. The disease has varied clinical presentations ranging in severity from patchy circumscribed alopecia, reticular pattern, ophiasis, sisaipho, diffuse, or incognito type to alopecia totalis and alopecia universalis. The various available treatment options include topical/intralesional steroids, topical immunotherapy/contact irritants, systemic steroids, and steroid-sparing agents like cyclosporine, azathioprine, methotrexate, and the JAK-STAT inhibitors...
2022: Indian Dermatology Online Journal
https://read.qxmd.com/read/36193241/sisaipho-alopecia-areata-treated-with-tofacitinib-and-oral-minoxidil
#6
Ronan Talty, William Damsky, Brett King
No abstract text is available yet for this article.
November 2022: JAAD Case Reports
https://read.qxmd.com/read/35462430/pseudo-fringe-sign-in-frontal-fibrosing-alopecia-like-cutaneous-lupus-erythematosus
#7
JOURNAL ARTICLE
Hudson Dutra Rezende, Ralph M Trüeb, Maria Fernanda Reis Gavazzoni Dias, Bianca Perez Bezerra de Lázaro, Gabriela Abasto Iglesias, Sandra Lopes Mattos Dinato, Karla Calaça Kabbach Prigenzi
BACKGROUND: marginal alopecia presents itself frequently in dermatological practice. For patients who present peripheral scalp hair loss, cicatricial and non-cicatricial alopecia should be considered, such as ophiasis, traction alopecia, and frontal fibrosing alopecia. In spite of the several types of hair loss that have been described in cutaneous lupus erythematosus, the "pseudo-fringe sign" had never been observed in such patents. OBJECTIVE: this paper aims at including the "pseudo-fringe sign" as another possibility of clinical manifestation in patients with cutaneous lupus erythematosus...
April 24, 2022: Journal of the European Academy of Dermatology and Venereology: JEADV
https://read.qxmd.com/read/35364216/phase-2-randomized-dose-ranging-trial-of-ctp-543-a-selective-janus-kinase-inhibitor-in-moderate-to-severe-alopecia-areata
#8
RANDOMIZED CONTROLLED TRIAL
Brett King, Natasha Mesinkovska, Paradi Mirmirani, Suzanne Bruce, Steve Kempers, Emma Guttman-Yassky, Janet L Roberts, Amy McMichael, Maria Colavincenzo, Colleen Hamilton, Virginia Braman, James V Cassella
BACKGROUND: Janus kinase (JAK) activation is suggested to have a pathological role in alopecia areata (AA). CTP-543, a deuterated compound that selectively inhibits JAK1 and JAK2, is being developed as an oral treatment for AA. OBJECTIVE: To assess the safety and efficacy of a 24-week regimen of CTP-543 in patients with chronic, moderate-to-severe AA. METHODS: In this phase 2, randomized, double-blind, placebo-controlled, sequential-design trial, patients were randomized to receive CTP-543 (4 mg, 8 mg, or 12 mg) or placebo every 12 hours for 24 weeks...
August 2022: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/34901176/a-retrospective-study-on-alopecia-areata-in-children-clinical-characteristics-and-treatment-choices
#9
JOURNAL ARTICLE
Christina Stefanaki, George Kontochristopoulos, Eleni Hatzidimitraki, Aravella Stergiopoulou, Alexandra Katsarou, Vasiliki Vosynioti, Eleni Remountaki, Dimitrios Rigopoulos
BACKGROUND: Although children are affected frequently with alopecia areata (AA), data are limited on clinical characteristics and treatment choices. MATERIALS AND METHODS: We retrospectively reviewed the records of the pediatric dermatology department over a 12-year period to identify children with AA. Clinical data were collected. RESULTS: Three hundred and sixty-four children with AA were identified, aged 1-12 years, 214 males and 150 females...
November 2021: Skin Appendage Disorders
https://read.qxmd.com/read/34504924/ophiasis-treated-with-dupilumab
#10
McKenna Abercrombie, Joseph Aleshaki, David Fivenson
No abstract text is available yet for this article.
October 2021: JAAD Case Reports
https://read.qxmd.com/read/34504923/time-to-loss-of-response-for-dupilumab-in-ophiasis-pattern-alopecia-areata
#11
Sarah Choe, Elan M Newman
No abstract text is available yet for this article.
September 2021: JAAD Case Reports
https://read.qxmd.com/read/34057862/evaluation-of-hla-class-i-and-hla-class-ii-allele-profile-and-its-relationship-with-clinical-features-in-patients-with-alopecia-areata-a-case-control-study
#12
JOURNAL ARTICLE
Yıldız Hayran, Melek Gunindi Korkut, Ayşe Öktem, Orhan Şen, Güneş Gür Aksoy, Füsun Özmen
BACKGROUND: Alopecia areata (AA) is an autoimmune disease where autoimmune dysregulations along with genetic susceptibility are hypothesized to play a role in pathogenesis. OBJECTIVE: The aim of this study in to evaluate HLA-A, HLA-B, HLA-C, HLA-DQB1 and HLA-DRB1 profile and its relationship with clinical features in AA patients. MATERIALS AND METHODS: Ninety-eight patients with AA and 100 healthy controls were included in the study. HLA-A, HLA-B, HLA-C, HLA-DQB1 and HLA-DRB1 frequencies were analyzed using polymerase chain reaction-sequence specific primers (PCR-SSP)...
May 31, 2021: Journal of Dermatological Treatment
https://read.qxmd.com/read/33991033/metabolic-syndrome-in-patients-with-alopecia-areata-a-case-control-study
#13
JOURNAL ARTICLE
Fahimeh Abdollahimajd, Nasim Niknezhad, Negin Bahreini, Shima Younespour, Nastaran Namazi
The aim of this study was to evaluate metabolic syndrome prevalence in patients with Alopecia Areata compared to controls. Sixty eligible patients with Alopecia Areata and 60 healthy subjects frequency matched for age and sex attending to our referral dermatology clinics from 2015 to 2017 were enrolled. Prevalence of metabolic syndrome and its components were compared between the two groups. Metabolic syndrome was only seen in seven patients (11.67%) and four controls (6.67%) without a significant difference (P = ...
July 2021: Dermatologic Therapy
https://read.qxmd.com/read/33961663/alopecia-areata-is-not-a-risk-factor-for-heart-diseases-a-10-year-retrospective-cohort-study
#14
JOURNAL ARTICLE
Heera Lee, You Chan Kim, Jee Woong Choi
Alopecia areata (AA) is an autoimmune skin disease caused by chronic inflammation of hair follicles. Chronic inflammatory skin diseases such as psoriasis and lupus erythematosus can increase the risk of cardiovascular diseases. However, the relationship between AA and heart diseases (HDs) remains unclear. Therefore, we conducted this retrospective cohort study to evaluate the risk of subsequent HDs in patients with AA. We reviewed 3770 cases of AA and from 18,850 age, sex, and income level-matched controls from the National Health Insurance Service-National Sample Cohort...
2021: PloS One
https://read.qxmd.com/read/33531746/validation-of-case-identification-for-alopecia-areata-using-international-classification-of-diseases-coding
#15
JOURNAL ARTICLE
Jonathan Lavian, Sara Jiayang Li, Eunice Yoojin Lee, Lindsey A Bordone, Fernanda C G Polubriaginof, Angela M Christiano, Arash Mostaghimi
BACKGROUND: Search algorithms used to identify patients with alopecia areata (AA) need to be validated prior to use in large databases. OBJECTIVES: The aim of the study is to assess whether patients with an International Statistical Classification of Diseases and Related Health Problems (ICD) 9 or 10 code for AA have a true diagnosis of AA. MATERIALS AND METHODS: A multicenter retrospective review was performed at Columbia University Irving Medical Center, Brigham and Women's Hospital, and Massachusetts General Hospital to determine whether patients with an ICD 9 codes (704...
September 2020: International Journal of Trichology
https://read.qxmd.com/read/32675968/ophiasis-alopecia-areata-treated-with-microneedling
#16
Usman Asad, Daniel Wallis, Michelle Tarbox
Alopecia areata (AA) is a T cell-mediated autoimmune disease resulting in the destruction of hair follicles. Ophiasis refers to a subtype of AA that presents as a symmetric, band-like hair loss pattern of the occipital, temporal, and parietal regions of the scalp. We present a case of a 58-year-old white man with AA, ophiasis pattern, who was treated with clobetasol 0.05% solution and four treatments of microneedling with triamcinolone over 6 months. He underwent gradual improvement, most notably on his left occipital scalp where his hair loss was most prominent, with near complete hair regrowth on his left occipital scalp...
July 2020: Proceedings of the Baylor University Medical Center
https://read.qxmd.com/read/32351186/pediatric-alopecia-areata
#17
REVIEW
Rebecca Afford, Alexander K C Leung, Joseph M Lam
BACKGROUND: Alopecia areata (AA) is a non-scarring hair loss disorder of autoimmune etiology. OBJECTIVE: To familiarize physicians with the clinical presentation, diagnosis, evaluation, and management of pediatric alopecia areata. METHODS: The search term "Alopecia areata" was entered into a Pubmed search. A narrow scope was applied to the categories of "epidemiology", "clinical diagnosis", "investigations", "comorbidities", and "treatment"...
2021: Current Pediatric Reviews
https://read.qxmd.com/read/32270396/cyclosporine-with-and-without-systemic-corticosteroids-in-treatment-of-alopecia-areata-a-systematic-review
#18
REVIEW
Joanna Nowaczyk, Karolina Makowska, Adriana Rakowska, Mariusz Sikora, Lidia Rudnicka
INTRODUCTION: Cyclosporine is commonly used in treatment for alopecia areata. It can be administered as a monotherapy or in combination with systemic corticosteroids, with various outcomes. METHODS: Efficacy of cyclosporine with and without systemic corticosteroids for alopecia areata was evaluated by a systematic review. Cochrane, EBSCOhost, Pubmed, Scopus and Web of Science databases were searched. Only studies published before January 2020 were included. RESULTS: A total of 2104 studies were initially examined, of which 14 were eligible for the systematic review...
June 2020: Dermatology and Therapy
https://read.qxmd.com/read/30677128/alopecia-areata-in-tunisia-epidemio-clinical-aspects-and-comorbid-conditions-a-prospective-study-of-204-cases
#19
JOURNAL ARTICLE
Aycha Arousse, Lobna Boussofara, Sana Mokni, Rima Gammoudi, Wafa Saidi, Amina Aounallah, Colandane Belajouza, Najet Ghariani, Mohamed Denguezli, Rafia Nouira
BACKGROUND: Alopecia areata (AA) is an autoimmune condition that usually presents as patchy, nonscarring hair loss. Autoimmune disorders and atopy are reported as comorbid conditions. We aimed to investigate the demographics, clinical characteristics, and associations of AA in Tunisian patients. METHODS: Demographic data, pattern of alopecia, age of onset, and associations were evaluated in 204 patients from January 2012 to June 2016. RESULTS: Two hundred and four cases of AA were seen...
July 2019: International Journal of Dermatology
https://read.qxmd.com/read/30318623/recalcitrant-alopecia-areata-responsive-to-leflunomide-and-anthralin-potentially-undiscovered-jak-stat-inhibitors
#20
JOURNAL ARTICLE
Kabir Sardana, Aastha Gupta, Ram K Gautam
Several treatment modalities are available for the management of alopecia areata (AA); however, no therapy is universally effective and treatment can be frustrating in severe cases, with low response and high recurrence rates. Recent studies show that the JAK/STAT pathway plays a central role in the pathogenesis of this disease by determining the crosstalk between the infiltrating CD8+ T cells and the hair follicles, suggesting a role of JAK inhibitors in the treatment of AA. However, reports on the off-label use of these more expensive targeted agents have shown variable results...
November 2018: Pediatric Dermatology
keyword
keyword
93735
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.